ProteoMediX is a spinoff company of ETH Zurich and specialized in the identification of novel biomarkers for the early detection of cancer and the personalized treatment thereof.

The first product currently developed is a blood-based test that enables the diagnosis of prostate cancer with significantly higher accuracy than today's clinical standard. This reduces unnecessary biopsies and thus results in significant cost savings for the healthcare system and less discomfort for the patient.


Our Awards and Supporters

Swiss Technology Award        Life Sciences Prize